Polyaromatic hydrocarbons in Ambient Particulate Matter (PM 2.5) mediate neurodegeneration through the olfactory-brain axis in C57BL/6 mice
Objective: To delineate the molecular mechanisms involved in bidirectional olfactory-brain-induced neurodegeneration caused by exposure to ambient particulate matter (PM2.5). Background: Air pollution has been linked…Association between changes in hippocampal volumes, cognition, and CSF markers in Parkinson’s Disease
Objective: To assess whether changes in hippocampal subfield volumes are associated with cognition or CSF β-amyloid 1–42 (Aβ42) levels in Parkinson’s Disease (PD). Background: Hippocampal…T1 MRI reveals differential hippocampal atrophy in Lewy body disorders with and without Alzheimer’s copathology
Objective: Determine whether MRI can identify differences in hippocampal volume between patients with Lewy body disorders with and without Alzheimer's copathology, and whether these differences…Melatonin attenuates the bidirectional Gut-Brain axis mediated inflammation caused by Ambient Particulate Matter (PM2.5) and averts neurodegeneration
Objective: To explore the therapeutic potential of melatonin in attenuating the PM2.5 induced inflammation and neurodegeneration through the Gut-brain axis in C57BL/6 mice. Background: The…Fibrinogen and CFAH: The two putative markers of Parkinson’s disease with cognitive impairment
Objective: To determine the pathogenic potential of fibrinogen and complement factor H (CFAH) in causing Parkinson’s disease (PD) with cognitive impairment (PDCI)-like symptoms using C57BL/6J…Association between Hippocampal Subfields, CSF Biomarkers, and Cognition in non-demented Parkinson’s patients
Objective: To determine whether hippocampal subfield volumes in non-demented Parkinson’s Disease (PD) are primarily predicted by cognition or CSF β-amyloid 1–42 (Aβ42) levels. Background: The…Therapy to Reduce dementia risk In Parkinson’s disease (TRIP): Proof-of-concept trial
Objective: The TRIP proof-of-concept study examines functioning of the hippocampal DG/CA3 subregion as a biomarker and therapeutic target for memory impairment in Parkinson’s Disease (PD).…The shared risk of apolipoprotein E ɛ4-allele on hippocampal volume across the spectrum of Alzheimer’s disease and dementia with Lewy bodies: Evidence from the Sunnybrook Dementia Study
Objective: To identify the association of apolipoprotein E ɛ4-allele (APOE-ε4) with hippocampal volumes across the spectrum of Alzheimer’s disease (AD) and dementia with Lewy bodies…Association between MAPT haplotype and hippocampal repetition suppression in Parkinson’s disease
Objective: We aimed to explore the relationship between the microtubule-associated tau gene (MAPT) haplotypes and response in the hippocampus to repeated stimuli in Parkinson’s disease…Relationships between specific subtypes of mild cognitive impairment and grey matter atrophy in Parkinson’s disease
Objective: Our aim was to investigate grey matter (GM) atrophy patterns in Parkinson’s disease patients with normal cognation (PD-NC) or with mild cognitive impairment(PD-MCI)using voxel…